检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years.

Naoki Ishiguro,Yoshiya Tanaka,Tsukasa Matsubara,Tatsuya Atsumi,Koichi Amano,Eiji Sugiyama,Kunihiro Yamaoka,Kevin Winthrop,Alan Kivitz,Gerd R Burmester,Jacques-Eric Gottenberg,Mark C Genovese,Franziska Matzkies,Ying Guo,Deyuan Jiang,Beatrix Bartok,Alena Pechonkina,Akira Kondo,Robin Besuyen,Tsutomu Takeuchi

Modern rheumatology（2023）

引用 2|浏览23
暂无评分
摘要
Long-term FIL treatment (median 1.5, maximum 2.5 years exposure) was well tolerated at 100- and 200-mg doses in Japanese patients with RA.
更多
查看译文
关键词
Filgotinib,Janus kinase,Japanese,Phase 3 clinical trials,rheumatoid arthritis
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要